Key Highlights

  • CLRO shares are lower by 15.65% today, changing hands at $4.22.
  • The Cortigent Merger agreement, tied to a Vivani Medical subsidiary, is dated July 1, 2026.
  • ClearOne intends to issue 12,500,000 shares to Vivani as merger consideration.
  • A planned unit offering would raise $10.0 million to $15.0 million at $3.50 per unit.
  • Cash on hand at the end of 2025 was about $0.7 million.

No Announcement Pinpointed for ClearOne's 15.65% Decline

ClearOne (NASDAQ:CLRO) stock is off 15.65% today at $4.22, and no company-specific announcement was found to explain the drop. Earlier this week the market Capitalization was listed near $14.7 million, when shares were around $5.49, and the stock is a penny stock.

The 52-week range spans $1.62 to $16.50, a swing that tracks a 1-for-15 reverse split in June 2025 and a sweeping Business restructuring.

Cash, cash equivalents and restricted cash were about $0.7 million at December 31, 2025. Remaining work includes support for legacy products, public company compliance duties and collection of receivables.

From Audio Conferencing Maker to a Pending Tie-Up With Cortigent

ClearOne once designed and sold professional audio conferencing, microphone and video collaboration equipment from Salt Lake City, Utah. In October 2025 it sold substantially all of its operating Assets and intellectual property to Biamp Systems, and it no longer makes or sells products.

Under a July 1, 2026 accord, a merger unit will fold into Cortigent, which then becomes a wholly owned ClearOne subsidiary. Cortigent belongs to Vivani Medical (NASDAQ:VANI), which is due to receive 12,500,000 ClearOne shares, while advisors would get 855,000 shares.

Stockholders signed off on the share issuance on August 25, 2026, ahead of closing. Completion still depends on financing, Nasdaq listing approval and reconstituting the board and management, and ClearOne could owe a $250,000 termination fee under certain conditions.

A new chief financial officer was brought on July 31, 2026, with the appointment taking effect once the Cortigent Acquisition is completed.

A $3.50 Unit Sale, Dilution Risk and a Going Concern Warning

The company filed to sell between 2,857,143 and 4,285,714 units at $3.50 apiece. Each unit contains one share and one Warrant exercisable at $10.00 for six months, producing gross proceeds of $10.0 million to $15.0 million, with the $10.0 million minimum required to close.

Outstanding shares of 2,675,412 would climb to between 5,532,554 and 6,961,126 after the offering, excluding warrant exercises and merger shares. Proceeds are designated for repaying a loan, advancing the Orion and Stroke Recovery systems, Manufacturing and working capital.

The auditor has raised substantial doubt about the company's ability to keep operating as a going concern, and the company received a Nasdaq continued-listing deficiency notice in April 2026. Shares now trade above the offering price.

Pending Financing and Listing Conditions Stand Between ClearOne and Its Merger

With no identified trigger for today's drop, the focus stays on the financing, dilution and listing conditions that must be met before the merger can close. The agreement can be terminated if the deal is not finished within 180 days of July 1, 2026.

The next scheduled data point is the Earnings report, estimated for November 13, 2026. Pricing or closing of the offering will also draw attention, as will any news on the Nasdaq listing review.